Enzalutamide combined with ADT reduces the risk of disease progression in Chinese men with mHSPC: The China ARCHES trial

Pembrolizumab + CCRT offers survival benefits to patients with previously untreated locally advanced cervical cancer: The ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Adjuvant abemaciclib + ET reduces the risk of invasive disease and relapse at 5-years in HR+, HER2- high-risk EBC: Interim analysis of the monarchE trial

First-line osimertinib + CT reduces risk of disease progression and death among EGFRm NSCLC patients with CNS metastases: Exploratory analysis of the FLAURA2 study

Clinically meaningful benefits with 2L or later line sacituzumab govitecan for patients with mTNBC in the real-world setting

Survival benefits of neoadjuvant nivolumab chemotherapy combination in patients with resectable NSCLC regardless of PD-L1 expression maintained in 3-year exploratory analysis from the CheckMate 816 trial

Enfortumab vedotin plus pembrolizumab significantly improves outcomes compared to chemotherapy in patients with previously untreated locally advanced metastatic urothelial carcinoma: The EV-302/KEYNOTE-A39 study

IC followed by CRT improves 5-year survival outcomes of patients with locally advanced cervical cancer: The phase 3 INTERLACE trial